Intra-articular 500-730 kDa hyaluronan (Hyalgan®) therapy in the management of osteoarthritis

Intra-articular 500-730 kDa hyaluronan (Hyalgan®) therapy in the management of osteoarthritis. Can a specific therapeutic profile be defined?

Article specifications

This review study was published in 2017 in Journal of Eur Rev Med Pharmacol Sci. (IF 2014:1.83) by Italian specialists. The present review is focused on the quite relevant amount of preclinical and clinical studies concerning a specific HA-based preparation (500-730 kDa native HA) and supporting its use as a tool for intra-articular therapy. They also include comparative studies to other HA preparations. The analysis of this experience allows to define a specific profile for 500-730 kDa HA as a tool for the management of osteoarthritis in terms of main mechanism of action, kinetics features and interaction with joint tissues, subpopulation of patients expected to obtain the highest benefit from the treatment, safety issues and impact on disease-cost.

 

Result

The abovementioned factors may also represent useful criteria to better characterize the specificities of each HA-based preparation and to achieve a more stratified categorization of this class of therapeutic tools.